H1 2022 Sales: €271m, up 6.1% +2.0% on a like-for-like basis H1 2022 Essentials Sales: €154m, up 9.8...
July 2022
STRONG PERFORMANCE ACROSS THE BOARD First half sales: €255m (up 33.5% at constant exchange rates)...
June 2022
Q1 2022 SALES: €135M (UP 5.5% AS REPORTED, UP 2.2% AT CONSTANT EXCHANGE RATES) Q1 2022 ESSENTIALS...
April 2022
ALL FINANCIAL INDICATORS UP Annual sales: €521m (up 21.9% as reported) Essentials sales: €296m (up...
March 2022
Total Group Sales: €521 million (up 21.9% as reported) Annual Sale of Essential products: €296...
January 2022
Felpreva® (tigolaner/emodepside/praziquantel) has been granted marketing authorisation by the...
November 2021
Regarding dissolution of Vetoquinol Zenoaq Co., Ltd and establishment of Vetoquinol Japan Co., Ltd
Vetoquinol (Headquarters: Lure, France, CEO: Matthieu Frechin, hereafter Vetoquinol) and Nippon...
October 2021
Third quarter revenues: €132 million +14.3% at constant exchange rates
Third quarter sales of Essential products: €75 million +26.0% at constant exchange rates Vetoquinol...
October 2021
Vetoquinol UK achieves bronze accreditation with Investors in the Environment
Veterinary pharmaceuticals company, Vetoquinol UK, has achieved bronze accreditation with Investors...
October 2021